GlucoTrack (GCTK) vs Phaos Technology (Cayman) (POAS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Phaos Technology (Cayman) is the larger company by market cap ($4.4 million vs $1.0 million), about 4.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GCTK | POAS |
|---|---|---|
| Share price | $1.03 | $0.138 |
| Market cap | $1.05M | $4.36M |
| 1-day change | -7.21% | -2.82% |
| EPS (TTM) | $-123.15 | $-0.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $123.75 | $7.40 |
| 52-week low | $1.00 | $0.132 |
| Distance from 52-week high | -99.17% | -98.13% |
| Average volume | 2.06M | 239.81K |
| Shares outstanding | 1.02M | 16.45M |
| Employees | 15 | 10 |
| Sector | Health Care | Industrials |
| Industry | Medical/Dental Instruments | Industrial Machinery/Components |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Phaos Technology (Cayman) is about 4.2 times larger than GlucoTrack by market value ($4.36M vs $1.05M).
- The two companies sit in different sectors: GlucoTrack in Health Care and Phaos Technology (Cayman) in Industrials.
About GlucoTrack
GCTK stock →GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
Health Care · Medical/Dental Instruments · 15 employees
About Phaos Technology (Cayman)
POAS stock →Phaos Technology Holdings (Cayman) Limited, through its subsidiary, Phaos Technology Pte. Ltd., engages in the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products in Singapore.
Industrials · Industrial Machinery/Components · 10 employees
GCTK vs POAS FAQ
Which is bigger, GlucoTrack or Phaos Technology (Cayman)?
Phaos Technology (Cayman) (POAS) is larger, with a market capitalization of $4.36M compared with $1.05M for GlucoTrack (GCTK).
Are GlucoTrack and Phaos Technology (Cayman) in the same industry?
No. GlucoTrack is in the Health Care sector, while Phaos Technology (Cayman) is in Industrials.